



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Consensus on daylight photodynamic therapy (dl-PDT) in Switzerland

Gaide, Olivier ; Hofbauer, Günther F L ; Hunger, Robert ; Mühlstädt, Michael ; Plaza, Tobias

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-114784>

Journal Article

Published Version

Originally published at:

Gaide, Olivier; Hofbauer, Günther F L; Hunger, Robert; Mühlstädt, Michael; Plaza, Tobias (2015). Consensus on daylight photodynamic therapy (dl-PDT) in Switzerland. *Dermatologica Helvetica*, 27(8):34-37.

► Chronischer Juckreiz

► HPV Impfstoff als Behandlung

► Konsens dI-PDT

► Prurit chronique

► Vaccin HPV comme traitement

► Consensus dI-PDT

Fokus Haare
Focus cheveux

DH

DERMATOLOGICA HELVETICA

Octobre 2015 - Volume 27 - N° 8

Revision Tarmed -
Zwischenbericht

Révision Tarmed -
Rapport intermédiaire



Klinische Fälle: Genf
Cas cliniques: Genève

Dieses Heft wurde für die Fortbildung der Schweizer Dermatologen dank einer Hilfe die folgenden Firmen realisiert:

Ce numéro a été réalisé grâce à une aide pour la formation continue des dermatologues suisses des firmes:



Pierre Fabre



SOMMAIRE

4	Journal Club
10	Fokus – Focus
16	SGDV – SSDV
26, 28, 30, 32, 34	Reports
37	Terminologie
38	Forum
39	Photo du mois
41	Industrie

RUBRIKEN DER DERMATOLOGICA HELVETICA -
RUBRIQUES DE DERMATOLOGICA HELVETICA
Weiterbildung - Formation continue

Redaktionsbüro, Bureau éditorial:

JH Saurat: Chefredaktor, Editeur en chef
M Harms: Chefredaktor StV, Editeur en chef adjointe
A Navarini: Assoziierter Redaktor, Rédacteur associé
C Hsu: Redaktor für die Social Media, Editeur sur les médias sociaux
Carine Herreras (derm.helv@bluewin.ch): Redaktionsbüro, Bureau éditorial
Atar Roto Presse SA, Genève: Druck, Impression

Sektionen, Sections:

JH Saurat: Journal Club, Focus
Chefärzte, Médecins chef-de-service: Case reports, coups d'œil (Koordination: Redaktionsbüro, Coordination: Bureau rédactionnel, C Herreras, derm.helv@bluewin.ch)
A Navarini: Peer-reviewed contributions
A Navarini: Weiterbildung der Assistenzärzte, Formation post-graduée des assistants
M Harms: Das diagnostische Photo, Photo du mois, terminologie
JP Grillet: Humor, Billet d'humour
J Hafner, C Mainetti: Tribune des Präsidenten, Tribune du président
M Tomasik: Neues aus dem Generalsekretariat, Nouvelles du secrétariat général
R Barbézat: Neue Mitglieder, Nouveaux membres
Neues aus den kantonalen Dermatologengesellschaften, den Kommissionen und Arbeitsgruppen, Nouvelles des sociétés cantonales de dermatologie et vénéréologie, des commissions et des groupes de travail (Koordination: Redaktionsbüro, Coordination: Bureau éditorial, C Herreras, derm.helv@bluewin.ch)
Neues aus der Industrie, Nouvelles de l'industrie (Koordination: Redaktionsbüro, Coordination: Bureau éditorial, C Herreras, derm.helv@bluewin.ch)

Ständige Kommission für Kommunikation, Commission permanente pour la communication:

AK Lapointe, AM Skaria: Redaktoren Westschweiz, Editeurs députés pour la Suisse romande
E Bianchi, F Pelloni: Redaktoren Tessin, Editeurs députés pour le Tessin
B. Schlagenhauff, J Hafner: Redaktoren deutsch-sprachige Schweiz, Editeurs députés pour la Suisse alémanique

e-mail: derm.helv@bluewin.ch

ISSN: 1420-2360

Authors instructions (peer reviews)

Size: Papers should comprise approximately 700-2000 words including figures, tables and references.
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.
Full address: The exact postal address of the corresponding author complete with postal code must be given.
Key words: For indexing purposes, a list of 3-5 key words in English is essential for all papers.
Abstract: Normally each paper needs an abstract of not more than 150 words. It should contain the following information: purpose of the study, procedures, results, conclusions and message of the paper. Abstracts submitted for publication in the section Original Papers should be structured as follows:
Background: What is the major problem that prompted the study
• Objective: What is the purpose of the study?
• Methods: How was the study performed?
Results: Most important findings?
• Conclusion: Most important conclusion?
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.
Formatting rules:
• Do not use any special page layout. If you would like to see what your manuscript looks like with embedded tables and illustrations, remember that we need text and illustrations as separate files!
• Enter your text continuously flush left. Do not use hard returns ("enter") within a paragraph, only at its end.
• Do not use footer and header functions.
• Use boldface and italics as well as sub- and superscript where appropriate.
• Use your word-processing program to insert Greek letters, mathematical symbols, etc.
Legends: The legends to your figures are part of the text and should be listed at the end of your text file.
Line Drawings
Black and White Half-Tone Images, Color Illustrations
Scans
• For processing and retouching scanned half-tone images, Photoshop is recommended. Please save the original scan as well as your processed version.
• Export black and white half-tones and color illustrations as TIF or EPS format, as close as possible to their anticipated size in print.
• Save them as separate files, not embedded in the text.
• Scanned line drawings must be digitalized with a resolution of at least 800, better 1000 dpi (dots per inch) after scaling.
• Scanned half-tone images should be digitalized with a final resolution of 300 dpi, a 12 bit grayscale accuracy and a density range of 2.8. Screen values must lie between 5% and 95%.
• Scanned color illustrations must be digitalized in RGB mode with a resolution of at least 300 dpi, a 32 bit accuracy and a density range of 2.8.
• Summary.
Make sure that your original has the resolution values in this table after scaling, otherwise the printing quality may be inadequate.
Detailed authors instruction will soon be available on our upcoming website.

ANZEIGENREGIE / RÉGIE DES ANNONCES

Carine HERRERAS

Tél. +41 79 667 32 48

E-mail: derm.helv@bluewin.ch

Warnung / Avertissement

Für den Inhalt ausserhalb des redaktionellen Teils (insbesondere Anzeigen, Industrieinformationen, Pressezitate und Kongressinformationen) übernehmen Redaktion und Verlag keine Gewähr. Eine Markenbezeichnung kann warenzeichenrechtlich geschützt sein, auch wenn bei ihrer Verwendung in dieser Zeitschrift das Zeichen* oder ein anderer Hinweis auf etwa bestehende Schutzrechte fehlen sollten.

L'éditeur et la rédaction déclinent toute responsabilité concernant le contenu non rédactionnel du périodique (en particulier les annonces, les informations émanant de l'industrie, les citations tirées de la presse et les informations issues de congrès). Une marque déposée peut jouir d'une protection légale même si elle est mentionnée dans le périodique sans le symbole * ou toute autre marque signalant, le cas échéant, une telle protection juridique.

Dosierungsangaben von Medikamenten:

Autoren und Verlag haben alle Anstrengungen unternommen, um sicherzustellen, dass Auswahl und Dosierungsangaben von Medikamenten im vorliegenden Text mit den aktuellen Vorschriften und der Praxis übereinstimmen. Trotzdem muss der Leser im Hinblick auf den Stand der Forschung, Änderungen staatlicher Gesetzgebungen und den unterbrochenen Fluss neuer Forschungsergebnisse bezüglich Medikamentenwirkung und -nebenwirkungen darauf aufmerksam gemacht werden, dass unbedingt bei jedem Medikament der Packungsprospekt konsultiert werden muss, um mögliche Änderungen im Hinblick auf Indikation und Dosis nicht zu übersehen. Gleiches gilt für spezielle Warnungen und Vorsichtsmassnahmen. Ganz besonders gilt dieser Hinweis für empfohlene neue und/oder nur selten gebrauchte Wirkstoffe.

Alle Rechte vorbehalten. Ohne schriftliche Genehmigung des Verlags dürfen diese Publikation oder Teile daraus nicht in andere Sprachen übersetzt oder in irgendeiner Form mit mechanischen oder elektronischen Mitteln (einschliesslich Fotokopie, Tonaufnahme und Mikrokopie) reproduziert oder auf einem Datenträger oder einem Computersystem gespeichert werden.

Posologie des médicaments:

Les auteurs et l'éditeur ont tout mis en œuvre pour s'assurer que le choix des médicaments et la posologie préconisés dans ce texte soient conformes aux recommandations et à la pratique au moment de la publication. Cependant, compte tenu des recherches en cours, des changements dans les législations et de l'afflux constant de données nouvelles concernant la thérapie médicamenteuse et l'effet des médicaments, il est vivement recommandé au lecteur de vérifier sur la notice jointe à chaque emballage si aucune modification n'est intervenue dans la posologie et si aucune nouvelle contre-indication ou précaution à prendre n'a été signalée. Cela est particulièrement important lorsque l'agent recommandé est nouveau ou peu employé. Tous droits de reproduction, même partielle, sous n'importe quelle forme, strictement réservés.

Consensus on daylight photodynamic therapy (dl-PDT) in Switzerland

Olivier Gaide¹, Gunther Hofbauer², Robert Hunger³, Michael Mühlstädt⁴ and Tobias Plaza⁵

¹ Dermatologie et Vénérologie, Centre hospitalier Universitaire Vaudois, Lausanne

² Dermatologie und Venereologie, Universität's Spital Zurich, Zurich

³ Dermatologie und Venereologie, Insel Spital, Bern

⁴ Dermatologie et Vénérologie, Hôpitaux Universitaires de Genève, Genève

⁵ Haut Zentrum Uster, Uster

Derm. Hel. 2015; 27(8):34-37

Daylight photodynamic therapy (dl-PDT) represents a novel and interesting technique for the efficient and painless treatment of field carcinogenesis. As there has been many questions regarding country-specific aspects that may impact on its practice, such as latitude and weather conditions, a group of specialists have gathered to write a position consensus on its use in Switzerland. It is based on the Journal of the European Academy of Dermatology and Venereology consensus from C.A. Morton et al. *Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis* JEADV 2015, but specifically addresses issues pertinent to our climate and health system. Its aim is to provide a simple practical guide for all practicing dermatology in Switzerland.

1. Key messages for daylight photodynamic therapy (dl-PDT)

- Methyl amino-levulinate (MAL) dl-PDT treatment is not inferior to conventional photodynamic therapy (cPDT) in several studies¹⁻⁷
- dl-PDT is better tolerated than cPDT¹⁻⁵
- Evidence regard the treatment of grade I and II AK of the face & scalp¹⁻⁵
- dl-PDT is a first-line treatment options for patient with AK grade I and II
- dl-PDT is a first line therapy in field cancerisation
- dl-PDT is a single-day treatment
- dl-PDT allows for the treatment of large fields

2. Who to treat ?

- According to the summary of product characteristics from Swissmedic (SmPC) MAL-PDT is indicated for the treatment of thin, non-hyperkeratotic actinic keratosis if other therapies are seen as inappropriate
- According to our panel of experts, dl-PDT may be a first-line treatment of patients suffering from actinic keratosis (AK) level I and II
- dl-PDT is also indicated for the treatment of AK level I in immunosuppressed patients (8)
- There is evidence for a partial treatment of AK grade III reported in area of AK I and II (reduction of AK III to AK II)

3. Weather conditions ?

- Aim a daylight exposure for 2 hours (range 1.5 – 2.5 hours)
- Sunny and shady places outside, direct sun irradiation is not mandatory
- dl-PDT is best used between 9:00 – 16:00 hours, with a guarantee of a mean irradiance (light intensity): 267 W/m² (44-601 W/m²) and optimal light intensity : >130W/m².
- Temperatures from 10 – 30 °C
- If patient feels too hot in direct sun light, the patient may relocate to the shade best at 25°C ambient temperature or above
- In rain and snow, dl-PDT treatment should not be performed
- In Summary, avoid any conditions in which the patient cannot stay comfortably outside for 2 hours.

4. Recommended steps/consultations for dl-PDT

4.1. Details on the pre-treatment for dl-PDT

- Keratolysis can be performed 1 to 6 days in advance.
- For keratolysis, urea 10 – 40%, or 5-10% salicylic acid, or mixes thereof (Excipial/Kerasal) are all fine
- Application of sun screen SPF ≥ 20. Use only sun screen with chemical filters
- Sun screen should be applied at least 15 min. before lesion preparation.

Do not use sun screen with physical filters such as zinc oxide, titanium dioxide or iron oxide, as these will absorb the visible light spectrum that activates proto-porphyrin IX and is essential for dl-PDT

4.2. Lesion preparation

- Remove crusts and roughen skin surface by one of the means below
 - Curettage. Skin should not bleed
 - Fractional laser: 10mJ/pulse, single pulse, 5% density
 - Microdermabrasion
 - Sandpaper ablation. Skin should not bleed (9)
 - Not recommended: tape stripping

4.3. Application of MAL 16% cream

- Thin layer of MAL 16% cream 2g on whole field treated area up to two full hand sized areas of

the patient for one session on the scalp or face.
Exceed this treatment area only with caution

4.4. Daylight exposure

- No later than 30 min after MAL 16% cream application
- 1.5 – 2.5 hours (target 2h) exposure in sunny and shady places outside

4.5. Follow-Up

- A) The patient did the treatment alone: the patient should remove remaining MAL 16% cream

by himself after 1.5 – 2.5 hours irradiation. A consultation by the physician after treatment is not mandatory. Patient should be advised to contact the physician in case of uncertainty or adverse events occurring after treatment

- B) If the treatment was done in the physician's office: MAL 16% cream will be removed in the physician's practice
- Follow-up visit at 3 months for evaluation of efficacy and safety should be scheduled

Procedure	Description	Consultation	Day
Diagnosis	Identification of treatment area(s) for AK I/II	1 st cons.	Baseline
Instruction of the patient	Explain the disease complex of actinic keratosis Illustrate dl-PDT treatment Explain the difference between daylight and UV irradiation (sun-light) Instruction for keratolysis using topical urea or salicylic acid or mix Instruction for sun protection cream application SPF \geq 20 at least 15 minutes before treatment starts	1 st cons.	Baseline
Pre-treatment for dl-PDT	keratolysis using urea or salicylic acid	Self-application by patient	1-6
Protection from UVA/UVB	Sun screen SPF \geq 20 application Use chemical filters only, no physical filters, at least 15 min before MAL application	Self-application by patient	7
Field lesion preparation for dl-PDT	Remove crusts and roughen skin surface by one of the following: Curettage Fractional laser: 10mJ/pulse, single pulse, 5% density Microdermabrasion Sandpaper abrasion	2 nd cons.	7
Patient instruction	Discuss checklist of to-do items Give instruction on the duration of the daylight treatment, the possibility to move and to relocate to shady areas if the sun is too hot	2 nd cons.	7
Application of MAL 16% cream	Apply a thin layer of MAL 16% cream 2g on whole field treated area up to two full hand sized areas of the patient for one session on the scalp or face. Exceed this treatment area only with caution	2 nd cons.	7
Daylight exposure	1.5 – 2.5 hours (target 2 hours) outside for patients Sunny and shady places outside Ambient temperature 10 – 30 °C After exposure, the patient or an assistant should wash off the remaining MAL-cream After exposure the patient should avoid sun-light	2 nd cons.	7
Post-treatment Consultation	If the patient performed the dl-PDT treatment outside of the physician's practice area, a follow-up visit right after the treatment should be performed	3 rd cons. (2 by patient)	7
Follow-Up	Evaluation of the efficacy of treatment and adverse events	4 th cons. (3 by patient)	60

5. Literature

1. Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. *Br J Dermatol* 2008; 158: 740–746.
2. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. *Br J Dermatol* 2009; 160: 1308–1314.
3. Wiegell SR, Fabricius S, Stender IM et al. A randomized, multicentre study of directed daylight exposure times of 1(1/2) vs. 2(1/2) h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. *Br J Dermatol* 2011; 164: 1083–1090.
4. Rubel DM, Spelman L, Murrell DF et al. Daylight PDT with methyl aminolaevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomised controlled trial. *Br J Dermatol* 2014; 171: 1164–1171.
5. Lacour J. Results of 2 randomised, controlled, phase III studies with Daylight-PDT in Australia and Europe. Euro-PDT 14th Annual Congress; April 4th–5th, 2014; Nice, France.
6. Wiegell SR, Wulf HC, Szeimies RM et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. *J Eur Acad Dermatol Venereol* 2012; 26: 673–679.
7. Morton CA. et al. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolaevulinate for actinic keratosis: a European consensus. *J EADV* 2015.
8. Togsverd-Bo K. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients - a randomized controlled trial. *BJD* 2015; 172(2):467-74.
9. William G. McEvitt et al. Treatment of Acne pits by abrasion with sandpaper

Venerologie

Das lateinische Ursprungswort ist:

Venus = lateinisch: Göttin der Liebe,
griechisch: Aphrodite

Die griechische Ursprungswort ist:

κύπρις = kypris = Cypris, Kypris andere (myzenische) Bezeichnung dieser Göttin

Venus die Göttin der Liebe ist für die Bezeichnung der Venerologie der Krankheiten die hauptsächlich durch Geschlechtsverkehr erworben werden herangezogen worden. Für dieselbe Bezeichnung ausgehend von dem griechischen Namen für diese Gottheit, der sich aber nicht auf Aphrodite bezieht sondern auf Cypris/Kypris was dann Crypidologie ergibt. Dieses Wort ist nicht mehr in Verwendung aber der gleiche Ursprung ergibt das Wort Crypidophobie und damit meint man die Furcht vor venerischen Erkrankungen oder Furcht vor Geschlechtsverkehr mit Prostituierten.

Vénérologie

Le nom latin d'origine est:

Venus = latin: déesse de l'amour
grecque: Aphrodite

Le mot grec d'origine est:

κύπρις = kypris = Cypris, Kypris autre nom mycénique de cette déesse

Venus, déesse de l'amour, a été choisie pour la dénomination de la vénérologie qui rassemble les maladies transmises principalement sexuellement. La dénomination à partir du nom grec de la déesse de l'amour n'est pas liée à Aphrodite mais à Cypris, un autre nom pour cette déesse, ce qui en résulte la cypridologie. Cette dénomination n'est cependant plus utilisée mais on retrouve la même origine dans le terme cypridophobie décrivant la crainte morbide des maladies vénériennes, plus précisément la crainte d'avoir des rapports avec les prostituées.